Firdapse: first treatment for Lambert-Eaton myasthenic syndrome

Firdapse (amifampridine) is the first drug to be approved for the treatment of Lambert-Eaton myasthenic syndrome.

Amifampridine improves muscle strength and increases resting compound muscle action potential through blockade of voltage-dependent potassium channels, which results in increased intracellular calcium concentrations and leads ultimately to enhanced neuromuscular transmission.

Treatment is given on a daily basis in 3 or 4 divided doses and should be initiated under the supervision of a physician experienced in the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Because of the rarity of the condition data on amifampridine are limited and the product information will therefore be reviewed annually by the European Medicines Agency.

View Firdapse drug record

Further information: BioMarin Europe

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more